Showing results (191-200 of 229) with videos related to
Sort By:
Pageof 23
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.Leukemia|March 28, 2018
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myelomaXiaohui Zhang, Hans C Lee, Fazal Shirazi, et al.JCI Insight|July 7, 2017
AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growthV Lokesh Battula, Phuong M Le, Jeffrey C Sun, et al.Oncotarget|November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypesPolina Matre, Juliana Velez, Rodrigo Jacamo, et al.Leukemia & Lymphoma|January 24, 2020
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.Pageof 23